Functional characterization of corticotropin-releasing factor type 1 receptor endogenously expressed in human embryonic kidney 293 cells

被引:35
作者
Dautzenberg, FM [1 ]
Higelin, J
Teichert, U
机构
[1] F Hoffmann La Roche & Co Ltd, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
[2] Max Planck Inst Expt Med, Dept Mol Neuroendocrinol, D-37075 Gottingen, Germany
关键词
receptor expression; ligand binding; cAMP; mRNA detection;
D O I
10.1016/S0014-2999(99)00915-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The endogenous expression in human embryonic kidney 293 (HEK293) cells of corticotropin-releasing factor (CRF) receptors was detected. High-affinity binding sites for human CRF (K-i = 3.6 nM), ovine CRF (K-i = 4.6 nM), rat urocortin ( K-i = 2.2 nM), sauvagine (K-i = 2.4 nM) and astressin (K-i = 4.3 nM) with the pharmacological characteristics for CRF type 1 (CRF1) receptors and B-max values of similar to 30 fmol/mg protein were determined. The four CRF receptor agonists nonselectively stimulated cAMP production in HEK293 cells at low agonist concentrations, whereas the antagonist astressin shifted the dose-response curve for ovine CRF significantly rightward. Transfection of the pcDNA3 Vector into HEK293 cells strongly reduced the expression of the endogenous CRF receptor. Northern blot analysis revealed the expression of a CRF1 transcript in human neuronal tissues, HEK293, human NTera-2 (NT2) carcinoma, Y-79 retinoblastoma and African green monkey kidney (COS-7) cells. Neither by Northern blot analysis nor by reverse transcriptase PCR (RT-PCR), the expression of CRF2 could be detected. In cAMP stimulation experiments, functional CRF receptors were detected in these cell lines. These data show that HEK293 and other cell lines endogenously express CRF1 receptors. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:51 / 59
页数:9
相关论文
共 49 条
[1]   RAPID DESENSITIZATION OF THE THYROTROPIN-RELEASING-HORMONE RECEPTOR EXPRESSED IN SINGLE HUMAN-EMBRYONAL-KIDNEY-293-CELLS [J].
ANDERSON, L ;
ALEXANDER, CL ;
FACCENDA, E ;
EIDNE, KA .
BIOCHEMICAL JOURNAL, 1995, 311 :385-392
[3]  
ANTONI FA, 1995, J BIOL CHEM, V270, P28055
[4]   The role of corticotropin-releasing factor in depression and anxiety disorders [J].
Arborelius, L ;
Owens, MJ ;
Plotsky, PM ;
Nemeroff, CB .
JOURNAL OF ENDOCRINOLOGY, 1999, 160 (01) :1-12
[5]   Human CRF2 α and β splice variants:: pharmacological characterization using radioligand binding and a luciferase gene expression assay [J].
Ardati, A ;
Goetschy, V ;
Gottowick, J ;
Henriot, S ;
Valdenaire, O ;
Deuschle, U ;
Kilpatrick, GJ .
NEUROPHARMACOLOGY, 1999, 38 (03) :441-448
[6]  
Bot G, 1998, J NEUROCHEM, V70, P358
[7]   Corticotrophin-releasing factor receptors: From molecular biology to drug design [J].
Chalmers, DT ;
Lovenberg, TW ;
Grigoriadis, DE ;
Behan, DP ;
DeSouza, EB .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (04) :166-172
[8]  
CHALMERS DT, 1995, J NEUROSCI, V15, P6340
[9]   Switching of the coupling of the beta(2)-adrenergic receptor to different G proteins by protein kinase A [J].
Daaka, Y ;
Luttrell, LM ;
Lefkowitz, RJ .
NATURE, 1997, 390 (6655) :88-91
[10]  
Dautzenberg FM, 1997, J NEUROCHEM, V69, P1640